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ABSTRACT
Purpose: We have shown previously that a preoperative paravertebral nerve block is associated with improved postoperative recovery in
microvascular breast reconstruction. The purpose of this study was to compare the outcomes of a complete enhanced recovery after surgery (ERAS) protocol with complete regional anesthesia coverage to our traditional care with paravertebral block.
Patients and methods: This was a retrospective cohort study of 83 patients who underwent autologous breast reconstruction by
T.M.M. between May 2014 and February 2018 at a tertiary academic center. Patients in the ERAS group were additionally administered
acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), gabapentin, a transversus abdominis plane block (liposomal or plain bupivacaine), and primarily oral opioids postoperatively. The patients were mobilized earlier with more rapid diet progression. All patients
received a preoperative paravertebral block.
Results: Forty-four patients in the ERAS cohort were compared with 39 retrospective controls. The 2 groups were similar with respect to
demographics and comorbidities. The ERAS cohort required significantly less opioids (291 vs 707 mg oral morphine equivalent, P < .0001)
with unchanged postoperative pain scores and a shorter time to oral only opioid use (16.0 vs 78.2 hours, P < .0001). Median length of stay
(3.20 vs 4.62, P < .0001) and time to independent ambulation (1.86 vs 2.88, P < .0001) were also significantly decreased in the ERAS cohort.
Liposomal bupivacaine use did not significantly affect the results (P ⩾ .2).
Conclusions: Implementation of a robust enhanced recovery protocol with complete regional anesthesia coverage was associated with
significantly decreased opioid use despite unchanged pain scores, with improved markers of recovery including length of stay, time to oral
only narcotics, and time to independent ambulation.
Keywords: Microvascular breast reconstruction, enhanced recovery, multimodal analgesia
RECEIVED: September 1, 2020. ACCEPTED: September 24, 2020.
TYPE: Original Research
Funding: The author(s) disclosed receipt of the following financial support for the
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Introduction

Autologous microvascular breast reconstruction is potentially
associated with superior cosmetic results, patient satisfaction, and
patient-reported quality of life relative to simpler methods.1,2
However, it is historically associated with a longer initial recovery
time and substantial postoperative pain.3,4 In the past IV patientcontrolled opioids were the mainstay of pain treatment. Our
patients were kept in nothing by mouth (NPO) status, had a urinary catheter, and remained on bedrest for over 24 hours after
surgery. These conservative practices were adopted to maximize
safety, but recent studies in this patient population have shown
them to be associated with delayed recovery.5-12
In May 2014, we added regional anesthesia in the form of a
T3 paravertebral block as a method to improve pain control and
postoperative outcomes after abdominally based autologous
microvascular breast reconstruction. This single intervention was

Declaration of conflicting interests: The author(s) declared the following
potential conflicts of interest with respect to the research, authorship, and/or publication of
this article: Independently, T.M.M. receives grant funding, consultant, and advisory board
fees from Allergan; investigator-initiated grant funding and consultant fees from RTI; and
advisory board fees from Viveve. These are entirely unrelated to this work. No other
authors report any disclosures.
CORRESPONDING AUTHOR: Ryan Guffey, Department of Anesthesiology, Washington
University School of Medicine, CB# 8054, 660 South Euclid Avenue, St. Louis, MO 63110,
USA. Email: rguffey@wustl.edu

associated with improved outcomes including less acute pain, a
more rapid transition to oral opioids, and decreased hospital stay
by a full day.13 Less than 2 years later we adopted a full enhanced
recovery protocol (enhanced recovery after surgery [ERAS])
adapted from the University of Toronto’s experience with pedicled flap reconstruction.11 This was done to both improve outcomes and also standardize treatment as part of a randomized
controlled trial on liposomal bupivacaine. The results of the trial
did not support any benefits to using liposomal bupivacaine as
part of an intraoperative transversus abdominis plane (TAP)
block, but it did not directly examine the effects of the enhanced
recovery protocol.14 This study compares the effects of the ERAS
protocol ( June 2016-February 2018) to our traditional care with
the addition of a paravertebral nerve block (May 2014-August
2015). We hypothesized that the ERAS cohort would require less
opioid pain medications and have improved markers of recovery.

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial
4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

Patients and Methods
Study design and population
This was a retrospective, single-surgeon, cohort study of 2
groups of patients who underwent abdominally based autologous breast reconstruction by the senior author (T.M.M.)
between May 2014 and February 2018. It was approved by the
Institutional Review Board (#201601064) at Washington
University in St. Louis. All patients underwent an abdominally
based autologous microvascular free flap breast reconstruction
at Barnes Jewish Hospital supplemented by a T3 thoracic paravertebral nerve block. The ERAS cohort was managed using a
complete enhanced recovery protocol implemented as part of
the “Analgesic Effects of Liposomal Bupivacaine Versus
Bupivacaine Hydrochloride Administered as a Transversus
Abdominis Plane Block After Abdominally Based Autologous
Microvascular Breast Reconstruction—A Prospective, SingleBlinded, Randomized Control Trial.”14 Cases completed
between August 7, 2015, and June 10, 2016, were excluded due
to phased implementation of the complete enhanced recovery
protocol. STROBE guidelines were adhered to during all
phases of this research.

Surgical techniques
All patients underwent immediate or delayed autologous
microvascular reconstruction with muscle-sparing transverse rectus abdominis myocutaneous (ms-TRAM), deep
inferior epigastric perforator (DIEP), or superficial inferior
epigastric artery (SIEA) flaps. Donor-site fascia was closed
either primarily or with mesh reinforcement at the discretion of T.M.M.

Historical controls (May 2014-August 2015)
This cohort of patients was managed traditionally with the
goal of minimizing potential damage to the flap in the early
postoperative period and allowing for rapid safe return to the
operating room if necessary (Supplemental Figure 1). Patients
were kept in NPO status for 36 hours after surgery on bedrest
with a urinary catheter and pain managed primarily by hydromorphone patient-controlled analgesia (PCA). Ambulation to
chair was allowed and the diet was advanced to clear liquids on
the second postoperative day. The urinary catheter and PCA
were discontinued as tolerated on postoperative day 3.
Preemptive analgesia consisted of preoperative ultrasoundguided parasagittal approach T3 paravertebral blocks with
15 mL of 0.5% bupivacaine injected per side for analgesia to
the chest wound and subcutaneous infiltration of bupivacaine
to the abdominal wound at the end of the case. Some of the
traditionally accepted ERAS components were already in
place during this cohort including preadmission counseling on
expectations, venous thromboembolism prophylaxis, antimicrobial prophylaxis, nausea and vomiting prophylaxis, flap
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monitoring, a nerve block to the breast wound in the form of
a paravertebral block, and standardized discharge criteria. The
benefits of the paravertebral block in this patient population
were studied previously.13

ERAS care ( June 2016-February 2018)
Our ERAS protocol includes almost all expected major components including preadmission counseling on expectations,
reduced perioperative fasting, venous thromboembolism prophylaxis, antimicrobial prophylaxis, nausea and vomiting prophylaxis, multimodal analgesia to decrease opioid requirements,
nerve blocks to all surgical wounds, early removal of lines, tubes,
and drains, early feeding, early mobilization, flap monitoring,
and standardized discharge criteria (Figure 1, Supplemental
Figure 2).14,15 Intraoperative intravenous fluid administration
was managed traditionally per the discretion of the anesthesia
team. Their long-standing goals for these cases are to administer crystalloid or colloid as needed to maintain mean arterial
pressure greater than 80% of preoperative values and greater
than 60 mm Hg without pressor administration. We believe that
reduced IV fluid use could be associated with unacceptably low
intraoperative blood pressure based on our prior experience
with attempting to reduce intraoperative IV fluid in this patient
population as well as recently published research.16
A complex standardized multimodal analgesia protocol was
adopted with the goal of decreasing postoperative pain and
patient request for opioid use. In addition to preoperative paravertebral blocks, scheduled acetaminophen 1000 mg QID,
celecoxib 200 mg BID, oxycontin 10 mg BID, and gabapentin
300 mg QHS were administered pre- and postoperatively. An
intraoperative TAP block was administered with either 266 mg
of liposomal bupivacaine or 75 mg of conventional bupivacaine
under direct visualization to the T6-L1 intercostal levels immediately prior to closure of the transverse abdominal incision as
further described in the liposomal bupivacaine trial.14 We have
previously shown there were no differences regarding pain control or any major outcome between liposomal bupivacaine or
conventional bupivacaine in this cohort.14 On postoperative day
(POD) zero, 1 mg of hydromorphone IV was made available
every hour for rescue analgesia. Beginning with POD 1, 5 to
10 mg of oral oxycodone was offered every 3 hours as well as
0.5 mg of hydromorphone IV every hour as needed for breakthrough pain. Nausea was preemptively controlled with scopolamine patches, intraoperative dexamethasone, and ondansetron.
Patients were encouraged to get out of bed to a chair on POD 1,
ambulate with assistance on POD 2, and ambulate independently on POD 3. The goal discharge date was the morning of
POD 3. Discharge criteria included reassuring flap exams by
physician staff, adequate pain control on oral medications, ability
to urinate spontaneously and to ambulate independently with
waist flexed if needed to minimize tension, as well as tolerance of
preoperative diet with return of bowel function.

Guffey et al
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ERAS

Traditional

– 1 2oz Water or carbohydrate drink at 5AM
before surgery
– NPO until POD 1
– Saline lock IV POD 2

– NPO after midnight before surgery
– NPO until POD 2
– Continuous IV fluids until POD 4

– Antibiotic
– Dexamethasone + ondansetron intraoperatively
– Ondansetron + enoxaparin + Docusate
postoperatively

– Antibiotic
– Dexamethasone + Ondansetron
intraoperatively
– Ondansetron + Enoxaparin +
Docusate postoperatively

– T3 Paravertebral block preoperatively
– Transversus abdominis plane block before
extubation
– No PCA
– Acetaminophen + NSAID + gabapentin +
Oxycontin scheduled before and after surgery
until discharge
– PRN Oxycodone and hydromorphone

– T
 3 Paravertebral block preoperatively
– P
 CA until POD 3
– Hydrocodone/acetaminophen POD3

– F
 lap checks Q1 hr POD0, Q2h POD1, Q4h
POD 3

– F
 lap checks Q1 hr POD0, Q2h POD1,
Q4h POD 3

– Removed POD 1

– Out of bed POD 1

– Removed POD 3

– Out of bed POD 2

Figure 1. Comparison of ERAS to traditional care.
ERAS indicates enhanced recovery after surgery; NPO, nothing by mouth; NSAID, non-steroidal anti-inflammatory drug; PCA, patient-controlled analgesia; POD,
postoperative day; PRN, as needed; Q, dosed every.

Data collection and outcome measures
Baseline patient demographic and clinical variables included
age, race, body mass index (BMI), American Society of
Anesthesiology (ASA) classification, preoperative opioid use,
and comorbidities. Baseline data was pulled directly from a
detailed history taken by the Center for Preoperative
Assessment and Planning at Barnes Jewish Hospital. Pathologic
variables included breast cancer side, history of chemotherapy,
radiation, and mastectomy type. Reconstructive variables
included laterality, timing of reconstruction, flap type, and
mode of abdominal fascia closure. Complications and return
trips to the operating room were also tabulated.
The primary outcome of this review is the total intra- and
postoperative opioid consumption calculated in oral morphine
equivalents. Secondary outcome measures are patient-reported
numerical rating scale (NRS) pain scores at 2, 12, 24, 48, and
72 hours postoperatively, duration of admission, amount of
antiemetic use, time to urinary catheter removal, time to independent ambulation, and time to oral only narcotics.

Statistical analyses
Our baseline data and demographics were compared with
Fisher exact test, Student’s t test, or Mann-Whitney U test
when appropriate. Normality was assessed using the ShapiroWilk test and QQ plots (SPSS Statistics for Windows,
Version 24.0. Armonk, NY: IBM Corp). Our primary outcome and most secondary outcomes were analyzed with the

Mann-Whitney U test due to skewed results distributions. To
better characterize the duration of admission data, a KaplanMeier analysis was also performed (Graphpad Prism 7 for
Windows San Diego, CA). No adjustments were made due to
near-perfect matching of baseline characteristics that are
known to affect postoperative pain.

Results
Patient population
From June 2016 through March 2018, 70 patients who underwent abdominally based microvascular breast reconstruction
after mastectomy were enrolled in “The Analgesic Effects of
Liposomal Bupivacaine Versus Bupivacaine Hydrochloride
Administered as a Transversus Abdominis Plane Block After
Abdominally Based Autologous Microvascular Breast
Reconstruction—A Prospective, Single-Blinded, Randomized
Control Trial.” Forty-four patients, or 22 in each group, completed the study. These patients comprise the ERAS cohort of
this study. Ten patients had their surgeries scheduled after the
trial closed. Eight were deemed ineligible because they were
later found to take preoperative narcotics daily, deviated significantly from the enhanced recovery protocol, or developed recurrent disease prior to surgery. Four patients withdrew their
consent and another 4 patients had missing data. In total, 83
patients are included in this study. A total of 39 patients
who underwent abdominally based microvascular breast reconstruction after mastectomy between May 2014 and August
2015 were consecutively reviewed as retrospective controls. No
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Table 1. Baseline demographic and clinical variables.
Historical (n = 39)

Age

ERAS (n = 44)

P

49

(9.0)

49

(9.5)

.82

32

(82%)

39

(89%)

.53

7

(18%)

5

(11%)

Weight (kg)

78.8

(13.4)

78.6

(13.5)

.94

BMI

29.2

(4.8)

28.6

(4.5)

.59

Race
White
Non-white

ASA Score (IQR)

2

(0)

2

(0)

.49

Home opioid use preoperatively

6

(15%)

5

(11%)

.75

DM

4

(10%)

1

(2%)

.18

GERD

11

(28%)

15

(34%)

.64

HTN

10

(26%)

5

(11%)

.15

Vascular disease

3

(8%)

0

(0%)

.10

Valvular disease

3

(8%)

2

(4%)

.66

CAD

0

(0%)

0

(0%)

—

Arrhythmia

0

(0%)

1

(2%)

1.00

CHF

0

(0%)

0

(0%)

—

Asthma or COPD

6

(15%)

5

(11%)

.75

OSA

2

(5%)

5

(11%)

.44

CKD

0

(0%)

1

(2%)

1.00

Stroke history

0

(0%)

0

(0%)

—

PONV history

11

(28.2)

13

(29.5)

1.00

Chemotherapy history

26

(67%)

34

(77%)

.33

Radiation history

23

(59%)

27

(61%)

1.00

Right

19

(48%)

22

(50%)

.58

Left

13

(33%)

10

(23%)

Bilateral

6

(15%)

8

(18%)

None

1

(3%)

4

(9%)

10

(26%)

14

(32%)

7

(18%)

2

22

(56%)

28

Breast cancer side

Breast cancer surgery side
Right
Left
Bilateral

.16

(4%)
(64%)

Abbreviations: ASA, American Society of Anesthesiology; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; OSA, obstructive sleep
apnea; CKD, chronic kidney disease; PONV, postoperative nauesa and vomiting; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ERAS, enhanced
recovery after surgery; GERD, gastroesophageal reflux disease; HTN, hypertension; IQR, interquartile range; SD, standard deviation.
Values are presented as mean (SD), median (IQR), or n (n%).

patients were excluded. There were no missing data for any outcome measures on included patients.

Baseline characteristics
The 2 groups were similar with respect to age, race, ASA score,
BMI, preoperative opioid use, comorbidities, and breast cancer
laterality (Table 1). There was also no statistically significant

difference between the 2 groups regarding reconstruction timing,
donor type (ie, DIEP/ms-TRAM/SIEA), donor-site closure
method, case duration, or complications (Table 2). Complications
were recorded if there was a need for bedside intervention or
return to the operating room. Despite not deliberately matching
the groups, the 2 cohorts are effectively matched for all risk factors for increased postoperative pain (age, BMI, ASA score, opioid use, case duration, chemotherapy, and radiation history).

Guffey et al
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Table 2. Baseline reconstructive variables.
Historical (n = 39)

ERAS (n = 44)

P

Reconstruction side
Right

10

(26%)

14

7

(18%)

2

22

(56%)

28

(64%)

33

(85%)

36

(82%)

.70

24

(62%)

26

(59%)

1.00

MS-TRAM

8

(20%)

9

(20%)

SIEA

1

(3%)

1

(2%)

TRAM

0

(0%)

1

(2%)

Left only

6

(15%)

7

(16%)

23

(59%)

23

(52%)

MS-TRAM

5

(13%)

10

(23%)

SIEA

0

(0%)

2

(4%)

TRAM

1

(3%)

1

(3%)

10

(26%)

8

(18%)

27

(69%)

26

(59%)

Mesh

5

(13%)

9

(20%)

No fascial closure necessary

7

(18%)

9

(20%)

Primary closure

18

(46%)

24

(54%)

Mesh

11

(28%)

10

(23%)

No fascial closure necessary

10

(26%)

10

(23%)

Left
Bilateral
Delayed reconstruction

(32%)

.16

(4%)

Right abdomen donor type
DIEP

Left abdomen donor type
DIEP

Right only

.51

Right abdomen closure
Primary closure

.57

Left abdomen Closure

Anesthesia case duration (hours)

.77

9.8

(2.0)

9.4

(1.7)

.33

Venous congestion

1

(3%)

2

(4%)

1.00

Partial flap loss/flap necrosis

2

(5%)

2

(4%)

1.00

Arterial insufficiency

0

(0%)

2

(4%)

.50

Abdominal wound dehiscence

4

(10%)

0

(0%)

.05

Donor-site seroma

1

(3%)

0

(0%)

.47

Donor-site hematoma

0

(0%)

1

(2%)

1.00

Complete flap loss

0

(0%)

0

(0%)

1.00

Breast hematoma

0

(0%)

0

(0%)

1.00

Abdominal cellulitis

1

(3%)

0

(0%)

1.00

Total

9

(23%)

7

(16%)

.58

Surgical complications

Abbreviations: DIEP, deep inferior epigastric perforator; ERAS, enhanced recovery after surgery; MS-TRAM, muscle-sparing transverse rectus abdominis muscle; SIEA,
superficial inferior epigastric artery; TRAM, transverse rectus abdominis muscle.
Values are presented as mean (SD) or n (n%).
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Table 3. Outcomes.
Historical (n = 39)

ERAS (n = 44)

P

Opioid usage (oral morphine equivalents, mg)
Intraoperative

145

(70)

102.5

(64)

.001

PACU and Floor

525

(370)

161

(166)

<.0001

PACU and Floor per day

129

(62)

62

(52)

<.0001

Total

707

(430)

291

(220)

<.0001

Pain scores
2 hours

3

(5)

2

(5)

12 hours

2

(5)

0.5

(3)

24 hours

4

(5)

2

(5)

48 hours

3

(3)

2

(4)

72 hours

2

(4)

1.5

(4)

78.2

(29)

16.0

(16)

<.0001

Time to oral only narcotics (hours)

.64

Duration of admission

4.62

(1.0)

3.20

(1.0)

<.0001

Duration of catheter

3.24

(0.9)

1.05

(0.8)

<.0001

Time to ambulation

2.88

(1.1)

1.86

(0.9)

<.0001

PACU

0

(0)

0

(0)

.60

Floor

0

(2)

0

(3)

.72

Total

0

(2)

0

(3)

.92

Antiemetic doses

Abbreviations: ANOVA, analysis of variance; ERAS, enhanced recovery after surgery; IQR, interquartile range; PACU, postoperative acute care unit.
Values are presented as median (IQR).
Mann-Whitney U or General Linear Model Repeated-Measures ANOVA (Pilal’s Trace) used where appropriate.
P < .007 is considered significant based on 7 concurrent comparisons (Bonferroni).

Figure 2. Duration of admission.
ERAS indicates enhanced recovery after surgery.

Outcomes
The median total opioid consumption in the ERAS group
(291 mg) was significantly decreased when compared with historical controls (707 mg, P < .0001) (Table 3). Opioid use also
revealed consistently significant between-group differences.
This effect was not associated with time when a segmental
regression analysis was performed for the historical and ERAS

periods (r2 = 0.006, P = .32, r2 = 0.009, P = .27). Despite markedly decreased opioid usage, pain scores were not significantly
different between groups. As one would expect with a protocol
that discourages IV PCA usage, time to oral only narcotic use
was significantly decreased by over 2 days (78.2 vs 16.0 hours,
P < .0001). Median total opioid use was significantly higher in
patients with delayed reconstruction (443 vs 339 mg, P = .045).
There were no other significant differences regarding reconstruction timing.
The ERAS protocol’s attempts to encourage ambulation,
remove the urinary catheter earlier, and support earlier discharge home were successful. Patients were able to independently ambulate 1 full day earlier as the protocol suggested
(1.86 vs 2.88 days, P < .0001). The duration of the urinary
catheter was significantly reduced from 3.24 days to 1.05 days
(P < .0001). Patients in the ERAS group were able to be discharged more than 1 full day earlier (3.20 vs 4.62 days,
P < .0001). A Kaplan-Meier analysis best characterizes this
(Figure 2, P < .0001). Liposomal bupivacaine or plain bupivacaine usage did not affect any of the above results (P ⩾ .2).14
There was no significant difference with respect to antiemetic
usage. This study was not powered to comment on differences

Guffey et al
in complication rates. There were no complications attributed
to the paravertebral or TAP blocks.

Discussion

The results of this study demonstrate that implementation of the
ERAS protocol was associated with unchanged pain scores
despite significantly reduced opioid consumption. Efforts to
improve the pace of recovery were successful with greater than
1 day decreases in time to oral only narcotics, duration of urinary
catheter, time to independent ambulation, and duration of admission. These results are consistent with the success of other ERAS
protocols previously implemented in breast reconstruction surgery. Our patients’ median NRS pain scores (0.5-2) and median
3.2 day duration of admission were similar to the lowest reported
by other comparable studies.5-7,9,12,17 A recent nationwide review
by Billig of the national inpatient sample showed a median length
of stay of 4 days (interquartile range [IQR], 3-5).18
We believe that analgesia to the chest wound is required for
maximum benefit. Four other ERAS protocols without regional
analgesia to the chest reported potentially higher median durations of admission: Bonde (6.2 days), Astanahe (4.8 days),
Alfonso (4.0 days), and Bardorf (3.9 days).5-7,17 Kouzantis
et al12 presented a protocol with a median duration of admission of 3.0 days without regional anesthesia to the chest wall,
but used IV ketamine, methadone, and a lidocaine infusion
started intraoperatively and continued for 24 hours postoperatively. These additional nonopioid methods of pain control may
be an alternative to nerve block for chest wall pain. However, a
lidocaine infusion with a bolus shortly after a TAP block as
administered Kouzantis’ study could potentially increase the
risk of intraoperative local anesthetic toxicity. It may be safer to
delay initiation of the lidocaine infusion protocol for 4 hours
after the TAP block or avoid the initial bolus. Similarly, it is
important to separate abdominal and chest wall blocks by the
most time possible to allow for higher dosage of local anesthetic without putting the patient at risk for local anesthetic
toxicity. This is why in our protocol the paravertebral block is
administered preoperatively and the abdominal TAP block is
placed at the end of the case, over 6 hours apart. After 6 hours,
the plasma level of local anesthetic is reduced by over 50%.19
Other potential alternatives to the paravertebral block for
analgesia could include intercostal, erector spinae, or serratus
anterior plane blocks.20-22 We perform paravertebral analgesia
due to its well described benefits in the literature and availability
of an experienced dedicated regional anesthesia team to perform
the nerve block preoperatively. Paravertebral blocks, IV lidocaine
infusions, and continuous local anesthetic wound infusions have
been associated with decreased acute and chronic postoperative
pain in multiple breast surgery studies.23 Of these, paravertebral
blocks are the only non-continuous option. They also have the
advantage of not affecting intraoperative blood pressure.15
It is our opinion that ERAS in microvascular breast
reconstruction should be the standard of care. Our study is
consistent with a recent meta-analysis that found significant
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improvement in opioid use and length of stay with no increase
in complications.24,25 With paravertebral as well as TAP analgesia, our protocol was unique in accomplishing this without
continuous infusions, and expensive or high-risk medications.
This protocol allowed us to consistently avoid using PCA. The
PCA tethers patients to an IV pole if they would like to walk
and still have pain relief. Multimodal analgesia without a PCA
and urinary catheter allows patients to ambulate much more
comfortably and effectively. Long-acting pain medications also
improve sleep quality. We believe these are the reasons our
patients were able to recover more quickly. It appears subjectively that our patients are more active and closer to their baseline activity level on postoperative day 3 with the ERAS
protocol than they were on day 5 before we initiated ERAS.
There have been multiple updates to the literature since
we created our ERAS protocol. In the future, we are considering stopping the oxycontin after the evening POD 0 dose,
increasing the dexamethasone dose to 8 mg, and omitting the
gabapentin26 unless taken at home.
We acknowledge there are limitations with this study.
Although the data from the ERAS group was collected prospectively, the historical data was collected retrospectively. As
the prospective data was collected as part of a randomized controlled trial, there were exclusion criteria for the prospective
portion of this study that were not present for the retrospective
cohort. Fortunately, there were no significant differences
regarding baseline characteristics as shown in Table 1.
There are many factors that can influence recovery that are
not easily studied in a retrospective cohort design. An individual’s frailty, anatomical variability, vascular status, and social
factors including family support, and willingness to comply
with treatment may have dramatic effects on one’s speed of
recovery. We have attempted to include all relevant medical
history, but retrospective results do not account for improvements in care with time. We have attempted to address this
with our non-significant segmental regression analysis and
near perfectly matched groups. All cases were also performed
by the same experienced surgeon, eliminating another source of
variability. Our results are not generalizable to all settings.

Conclusions

In this cohort study, implementation of a robust enhanced
recovery protocol with plain or liposomal bupivacaine was
associated with significantly decreased opioid use despite
unchanged pain scores, with improved markers of recovery
including length of stay, time to oral only narcotics, and time to
independent ambulation.
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